13^th Annual Congress on Pulmonary and Critical Care October 23-24, 2025 Paris, France

Dr. Himanshu Narayan Singh is a Senior Research Scientist at Memorial Sloan Kettering Cancer Center, New York, where his research focuses on the treatment-driven evolution of high-grade tumors. He investigates the complex interplay between aggressive tumor microenvironments and disease progression, particularly in response to various therapies.

Genomics & Epigenomics; Bioinformatics; Cancer Biology

Hiroaki Kume obtained his MD from Toyama Medical and Pharmaceutical University in 1982. He has completed his PhD in Department of Medicine (II), Nagoya University School of Medicine in 1990, and postdoctoral studies from School of Veterinary Medicine, University of Pennsylvania (Dr. Michael I. Kotlikoff’s Lab). Currently, he works at Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine and Department of Respiratory Medicine, Rinku General Medical Center, Izumisano City, Osaka 598-8577, Japan, and focuses on investigating the characteristics of COPD with the goal of rational therapy for COPD.

COPD Asthma

Dr. Yong-Xiao Wang has been a Full Professor in Albany Medical College (USA) since 2006. Dr. Wang has had extensive research experience in basic, translational and drug research concerning pulmonary hypertension, asthma, chronic obstructive pulmonary disease, diabetes, and cardiac arrhythmia for over 30 years. As the Principal Investigator, he has/had numerous NIH R01 research awards, AHA Established Investigator Award, and various other grants, for which he often holds/held 2 – 3 NIH R01 grants with other awards each year. As the corresponding author, first author and key contributor, he has had numerous publications in highly peer-reviewed journals including Antioxid Redox Signal (impact factor: 8.209), Proc Natl Acad Sci USA (9.432), Nature (34.480), Circ Res (9.214), etc. Dr. Wang has been the editor of academic books in the field including one entitled by “Redox Signaling in Health and Disease Pulmonary Vasculature” that has been confirmed for publication by Springer (New York). Dr. Wang has also served as the editorial board member and/or section editor for the Clinical and Translational Medicine, Pulmonary Circulation and several other journals.

Pulmonary hypertension, Asthma, Chronic Obstructive Pulmonary Disease, Diabetes, and Cardiac Arrhythmia

Amnon Ariel is the immediate past president of the Israel Society of Pulmonology, and current lead of Clalit Heathcare Services COPD program. He is currently involved in clinical and organizational endeavors of improving airway disease diagnosis management and related database research in Clalit Healthcare Services (insuring 55 percent of the population in Israel). He is co-author of the 2004 Canadian COPD Guidelines and the 2017 Israeli Position Paper of the diagnosis and management of COPD in the community.

COPD

Nobuaki Miyahara graduated from Hiroshima University School of Medicine in 1988. He has completed his PhD in Department of Medicine II, Okayama University School of Medicine in 1994. He had done research on allergic airway inflammation at the National Jewish Health in Denver, CO, USA (Dr. Erwin Gelfand’s Lab) from 2001 to 2008. Currently, he works at Department of Medical Technology, Okayama University Graduate School of Health Sciences, and Department of Allergy and Respiratory Medicine, Okayama University Hospital.

COPD Asthma

Dr.Yong-Xiao Wang has been a Full Professor in Albany Medical College (USA) since 2006.Dr. Wang has had extensive research experience in basic,translational and drug research concerning pulmonary hypertension, asthma, chronic obstructive pulmonary disease, diabetes, and cardiac arrhythmia for over 30 years. As the Principal Investigator, he has/had numerous NIH R01 research awards, AHA Established Investigator Award, and various other grants, for which he often holds/held 2 – 3 NIH R01 grants with other awards each year. As the corresponding author, first author and key contributor, he has had numerous publications in highly peer-reviewed journals including Antioxid Redox Signal (impact factor: 8.209), Proc Natl Acad Sci USA (9.432), Nature (34.480), Circ Res (9.214), etc. Dr. Wang has been the editor of academic books in the field including one entitled by “Redox Signaling in Health and Disease Pulmonary Vasculature” that has been confirmed for publication by Springer (New York). Dr. Wang has also served as the editorial board member and/or section editor for the Clinical and Translational Medicine, Pulmonary Circulation and several other journals.

Pulmonary hypertension, Asthma, Chronic obstructive pulmonary disease